Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous HPV-E6/E7-targeting T cells

A preparation of autologous T lymphocytes that are specifically reactive towards the human papillomavirus (HPV) viral oncoproteins E6 and E7, with potential immunomodulating and antineoplastic activities. Following leukapheresis and ex vivo priming and expansion, the autologous HPV E6/E7-targeting T cells are re-introduced into the patient, where they target and kill tumor cells expressing these HPV tumor-associated antigens (TAAs). HPV E6 and E7 are overexpressed on certain tumor cell types and play key roles in tumor cell proliferation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous HPV E6/E7-reactive T cells

autologous HPV-E6/E7-targeting T cells

Search NCI's Drug Dictionary